204 related articles for article (PubMed ID: 36273042)
1. UBE2O promotes lipid metabolic reprogramming and liver cancer progression by mediating HADHA ubiquitination.
Ma M; Zhang C; Cao R; Tang D; Sang X; Zou S; Wang X; Xu H; Liu G; Dai L; Tian Y; Gao X; Fu X
Oncogene; 2022 Nov; 41(48):5199-5213. PubMed ID: 36273042
[TBL] [Abstract][Full Text] [Related]
2. UBE2O promotes hepatocellular carcinoma cell proliferation and invasion by regulating the AMPKα2/mTOR pathway.
Shi Z; Liu R; Lu Q; Zeng Z; Liu Y; Zhao J; Liu X; Li L; Huang H; Yao Y; Huang D; Xu Q
Int J Med Sci; 2021; 18(16):3749-3758. PubMed ID: 34790050
[TBL] [Abstract][Full Text] [Related]
3. Diverse roles of the E2/E3 hybrid enzyme UBE2O in the regulation of protein ubiquitination, cellular functions, and disease onset.
Ullah K; Zubia E; Narayan M; Yang J; Xu G
FEBS J; 2019 Jun; 286(11):2018-2034. PubMed ID: 30468556
[TBL] [Abstract][Full Text] [Related]
4. MiR-612 regulates invadopodia of hepatocellular carcinoma by HADHA-mediated lipid reprogramming.
Liu Y; Lu LL; Wen D; Liu DL; Dong LL; Gao DM; Bian XY; Zhou J; Fan J; Wu WZ
J Hematol Oncol; 2020 Feb; 13(1):12. PubMed ID: 32033570
[TBL] [Abstract][Full Text] [Related]
5. Ubiquitin-conjugating enzyme UBE2O regulates cellular clock function by promoting the degradation of the transcription factor BMAL1.
Chen S; Yang J; Zhang Y; Duan C; Liu Q; Huang Z; Xu Y; Zhou L; Xu G
J Biol Chem; 2018 Jul; 293(29):11296-11309. PubMed ID: 29871923
[TBL] [Abstract][Full Text] [Related]
6. High Level of Ubiquitin Conjugate Enzyme E2O Indicates Poor Prognosis of Patients with Hepatocellular Carcinoma.
Lan SY; Ding Y; Wang C; Fang J; Ren C; Liu JL; Kang H; Chang Y
Curr Med Sci; 2023 Feb; 43(1):93-103. PubMed ID: 36269535
[TBL] [Abstract][Full Text] [Related]
7. A UBE2O-AMPKα2 Axis that Promotes Tumor Initiation and Progression Offers Opportunities for Therapy.
Vila IK; Yao Y; Kim G; Xia W; Kim H; Kim SJ; Park MK; Hwang JP; González-Billalabeitia E; Hung MC; Song SJ; Song MS
Cancer Cell; 2017 Feb; 31(2):208-224. PubMed ID: 28162974
[TBL] [Abstract][Full Text] [Related]
8. UBE2O reduces the effectiveness of interferon-α via degradation of IFIT3 in hepatocellular carcinoma.
Li H; Liu Y; Cheng C; Wu Y; Liang SH; Wu L; Wang H; Tu CY; Yao HH; Meng FZ; Zhang B; Wang W; Wang JB; Liu LX
Cell Death Dis; 2023 Dec; 14(12):854. PubMed ID: 38129382
[TBL] [Abstract][Full Text] [Related]
9. UBE2O targets Mxi1 for ubiquitination and degradation to promote lung cancer progression and radioresistance.
Huang Y; Yang X; Lu Y; Zhao Y; Meng R; Zhang S; Dong X; Xu S; Wu G
Cell Death Differ; 2021 Feb; 28(2):671-684. PubMed ID: 32901121
[TBL] [Abstract][Full Text] [Related]
10. New Insights into the Role of E2s in the Pathogenesis of Diseases: Lessons Learned from UBE2O.
Hormaechea-Agulla D; Kim Y; Song MS; Song SJ
Mol Cells; 2018 Mar; 41(3):168-178. PubMed ID: 29562734
[TBL] [Abstract][Full Text] [Related]
11. A muscle-specific UBE2O/AMPKα2 axis promotes insulin resistance and metabolic syndrome in obesity.
Vila IK; Park MK; Setijono SR; Yao Y; Kim H; Badin PM; Choi S; Narkar V; Choi SW; Chung J; Moro C; Song SJ; Song MS
JCI Insight; 2019 Jul; 4(13):. PubMed ID: 31292296
[TBL] [Abstract][Full Text] [Related]
12. UBE2O promotes the proliferation, EMT and stemness properties of breast cancer cells through the UBE2O/AMPKα2/mTORC1-MYC positive feedback loop.
Liu X; Ma F; Liu C; Zhu K; Li W; Xu Y; Li G; Niu Z; Liu J; Chen D; Li Z; Fu Y; Qian C
Cell Death Dis; 2020 Jan; 11(1):10. PubMed ID: 31907353
[TBL] [Abstract][Full Text] [Related]
13. E3 ligase ZFP91 inhibits Hepatocellular Carcinoma Metabolism Reprogramming by regulating PKM splicing.
Chen D; Wang Y; Lu R; Jiang X; Chen X; Meng N; Chen M; Xie S; Yan GR
Theranostics; 2020; 10(19):8558-8572. PubMed ID: 32754263
[No Abstract] [Full Text] [Related]
14. The ubiquitin-conjugating enzyme UBE2O modulates c-Maf stability and induces myeloma cell apoptosis.
Xu Y; Zhang Z; Li J; Tong J; Cao B; Taylor P; Tang X; Wu D; Moran MF; Zeng Y; Mao X
J Hematol Oncol; 2017 Jul; 10(1):132. PubMed ID: 28673317
[TBL] [Abstract][Full Text] [Related]
15. Autodeubiquitination protects the tumor suppressor BAP1 from cytoplasmic sequestration mediated by the atypical ubiquitin ligase UBE2O.
Mashtalir N; Daou S; Barbour H; Sen NN; Gagnon J; Hammond-Martel I; Dar HH; Therrien M; Affar el B
Mol Cell; 2014 May; 54(3):392-406. PubMed ID: 24703950
[TBL] [Abstract][Full Text] [Related]
16. Gain of UBE2D1 facilitates hepatocellular carcinoma progression and is associated with DNA damage caused by continuous IL-6.
Zhou C; Bi F; Yuan J; Yang F; Sun S
J Exp Clin Cancer Res; 2018 Nov; 37(1):290. PubMed ID: 30482241
[TBL] [Abstract][Full Text] [Related]
17. Mechanism of client selection by the protein quality-control factor UBE2O.
Yip MCJ; Sedor SF; Shao S
Nat Struct Mol Biol; 2022 Aug; 29(8):774-780. PubMed ID: 35915257
[TBL] [Abstract][Full Text] [Related]
18. UBE2O and USP7 co-regulate RECQL4 ubiquitinylation and homologous recombination-mediated DNA repair.
Huang Q; Qin D; Pei D; Vermeulen M; Zhang X
FASEB J; 2022 Jan; 36(1):e22112. PubMed ID: 34921745
[TBL] [Abstract][Full Text] [Related]
19. UBE2T-regulated H2AX monoubiquitination induces hepatocellular carcinoma radioresistance by facilitating CHK1 activation.
Sun J; Zhu Z; Li W; Shen M; Cao C; Sun Q; Guo Z; Liu L; Wu D
J Exp Clin Cancer Res; 2020 Oct; 39(1):222. PubMed ID: 33087136
[TBL] [Abstract][Full Text] [Related]
20. Defects in long-chain 3-hydroxy acyl-CoA dehydrogenase lead to hepatocellular carcinoma: A novel etiology of hepatocellular carcinoma.
Khare T; Khare S; Angdisen JJ; Zhang Q; Stuckel A; Mooney BP; Ridenhour SE; Gitan RS; Hammoud GM; Ibdah JA
Int J Cancer; 2020 Sep; 147(5):1461-1473. PubMed ID: 32115688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
